Biotech
Bambusa Therapeutics
Bambusa Therapeutics raises $90M Series A at $400M valuation
San Francisco, CAFebruary 15, 20251 min read
Total Raised
$90M
Valuation
$400M
Latest Round
Series A
Employees
60+
Bambusa Therapeutics: Series A Funding Round
Bambusa Therapeutics has successfully raised $90M in Series A funding, reaching a valuation of $400M.
Company Overview
Bispecific antibodies for immunology
Funding Details
The Series A round was led by Arch Venture Partners, with participation from Foresite Capital.
Company Information
- Headquarters: San Francisco, CA
- Founded: 2022
- Employees: 60+
- Category: Biotech
Investment
Bambusa Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Arch Venture Partners: Verified investor in Series A
- Foresite Capital: Verified investor in Series A
Company Info
Headquarters
San Francisco, CA
Founded
2022
Team Size
60+
Last Round
$90M(Feb 2025)
Investors (2)
A
Arch Venture PartnersLeadLead Investor
Verified investor in Series A
F
Foresite CapitalInvestor
Verified investor in Series A
Share
Related Reports
Biotech
AusperBio
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
David Chen
Dec 30, 2025
0 min read•$73M Series B
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free